AAV Serotype Blastu2122 Kit
如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱: AAV Serotype Blastu2122 Kit
產(chǎn)品型號(hào): AAV099
產(chǎn)品展商: 其他品牌
產(chǎn)品文檔: 無(wú)相關(guān)文檔
簡(jiǎn)單介紹
AAV Serotype Blastu2122 Kit
AAV Serotype Blastu2122 Kit
的詳細(xì)介紹
Description
? AAV is a small, non-enveloped virus from the family infecting both dividing and non-dividing cells. The choice of cell types, serotypes, and the optimal multiplicity of infection (MOI) play a key role in influencing transduction efficiency during an experiment. Thus, it is crucial to develop the optimal criteria of AAV transduction for your research. Our AAV Serotype Blast? Kit will provide you the answer you are looking for. This AAV serotype starter kit includes 9 pre-packaged helper-free Adeno-associated viruses with GFP expressions. You can establish all foundation standards with AAV Serotype Blast? Kit and enhance your research findings in a timely manner. Saving time and extra amount effort, all you need to do is try our kit.
Figure 1: 293T cells were seeded at 20,000 cells/well in 24-well plate. Next day they were transduced with different serotype of AAV at a MOI of 500. Fluorescent images are taken 5 days after infection.This image shows that serotype 1,2 and 3 is best for this cell line while serotype 4-6 show very low transduction efficiency. Thus, AAV Serotype Blast? Kit can help decide which serotype should be used for delivery of gene in this specific cell line.
Advantages of abm’s AAV Serotype Blast? Kit
- Serotype 1-9 available in the kit for testing
- The kit is easy to use
- Simplify your transduction optimization process
- Helps you to draw accurate conclusions on suitable serotypes for your cell lines
- This AAV serotype starter Kit has a large range of the cell types which can be tested against
- Saves you time for your research
References:
- Ellis, et al. " A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype." Virology Journal 10(74): (2013).
- Schultz, B.R. et al. " Recombinant Adeno-associated Virus Transduction and Integration." The American Society of Gene Therapy 16(7):1189-1199 (2008). DOI: doi:10.1038/mt.2008.103.
- Pajusola, K. et al. " Cell-Type-Specific Characteristics Modulate the Transduction Efficiency of Adeno-Associated Virus Type 2 and Restrain Infection of Endothelial Cells." Journal of Virology 76(22):11530-11540 (2002). DOI: 10.1128/JVI.76.22.11530–11540.2002.
- Fisher, K.J. et al. "Transduction with Recombinant Adeno-Associated Virus for Gene Therapy Is Limited by Leading-Strand Synthesis." American Society for Microbiology – Journal of Virology 70(1):1520-1532 (1996).